Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute bioavailability study of BI 1291583 in healthy men
NL-OMON60721Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of verducatib, sponsored by Boehringer Ingelheim. Primary endpoint: AUC0-∞. Started Dec 2023; status: completed.
02
Drugs
verducatib
Beyond the preview
Go deeper on NL-OMON60721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60721.